News CMS's Medicare price negotiations start round three The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.
News UCB bags FDA okay for first drug to treat rare disease TK2d People living with thymidine kinase 2 deficiency (TK2d), a vanishingly rare and often fatal genetic disorder, finally have an approved therapy.
News UCB drug for rare disease TK2d boosts survival UCB's experimental medicine for TK2d, currently under regulatory review, offers hope to patients with the devastating rare disease.
News Data at EULAR back Biogen, UCB's first-in-class lupus drug Hopes rise for a new treatment option for people living with lupus, after UCB and Biogen reveal phase 3 data with their anti-CD40L antibody DZP.
News J&J's 'Swiss army knife' drug gets first FDA approval Johnson & Johnson has its first regulatory approval for FcRn blocker Imaavy, getting a green light in the US for generalised myasthenia gravis (gMG).
News UCB's non-cannabis drug for severe epilepsy gets NHS okay Around 1,400 patients with Lennox-Gastaut Syndrome will be eligible for NHS treatment with UCB's Fintepla after a NICE recommendation.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
